Regulators and reimbursement bodies are increasingly turning to real-world evidence (RWE) to understand the long-term value of drugs, in particular novel therapies. Here, Mariam Bibi, Senior Director, Global RWE at PRMA Consulting, a member of Fishawack Health, reveals her advice for developing a successful strategy that meets the needs of every stakeholder. Fishawack Health
Fishawack Health announces its expanded global Value, Evidence, and Access (VEA) capability for biopharmaceutical and medical technology companies, with a suite of end-to-end services spanning product lifecycle, coupled with unsurpassed geographic reach. Fishawack Health
Milo Elmir, Managing Consultant, examines the trends changing the behaviors of 3 healthcare stakeholders—patients, payers, and healthcare professionals—and explores how building human-centered solutions will help biopharmaceutical and medical technology companies drive better engagement. Fishawack Health
Annemarie Armstrong, Executive Vice President, US Head of Client Services, shares the key considerations for launching a first commercial product, particularly on a rapid timeline. Fishawack Health
The pandemic has shown that public trust in promising new medical technologies is far from a given. Senior Writer Tom Vandyck at StoneArch, a member of Fishawack delves into the right approach to help companies with breakthrough innovations in their pipeline build consumer confidence. Fishawack Health
Fishawack Health welcomes FIDE, an independent organization providing its clients with insight from clinical key opinion leaders in inflammatory dermatology Fishawack Health